Warning: Constant WP_CACHE already defined in /home/bicollgroup/public_html/wp-config.php on line 8
Publications - Bicoll GmbH

Publications

The right match – German SMEs: Challenges, Strategies and Success in a Competitive China

GC Ticker: bi-monthly newsletter of the German Chamber of Commerce, 4, 2010, p. 35

Take a clever business idea, add some profound financing and set up facilities in China is not a
one size fits all guideline for stepping into one of Asia’s biggest economies”, remarked Dr. Kai La-
mottke, General Manager at Bicoll Biotechnology (Shanghai) Co. Ltd. Back in 2000 the company
was founded as a private biopharmaceutical enterprise in Germany offering pre-clinical support
in the area of drug discovery from natural products and medicinal chemistry. Before planning to
setting up its subsidiary in China in 2001, the company’s management was aware that participat-
ing in China’s growth is not a simple proposition. It was clear that building up domestic contacts
first and considering that conducting business in China is different, requiring flexibility and adapt-
ability were necessary components of Bicoll’s strategy, strengthened by the fact that no examples
existed as guidance for the successful establishment of a company like Bicoll. Therefore, a novel
business model tailored for the parallel set-up in Europe and in China was needed to address this.
An early positive cash-flow was one of the most important milestones in Bicoll’s concept.

Read more

Results of research on aurora kinase inhibitors announced

BICOLL GmbH and EMBL have announced the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.

Aurora kinases have gained a great deal of attention as possible anticancer drug targets because these serine–threonine kinases are frequently overexpressed in human tumours.
For a research project on genetic instability and cellular proliferation caused by aurora kinase expression in several cancer entities, including multiple myeloma, the group of Dr Joe Lewis, Head of Chemical Biology Core Facility at the European Molecular Biology Laboratory (EMBL) Heidelberg, has been searching for novel aurora kinase inhibitors supplementing already known clinical aurora kinase inhibitors such as VX680.
The search for promising compounds was based on the screening of ProfilesTM from BICOLL’s library of plant metabolites.
Dr Lewis explained: ‘Bicoll’s idea of using pooled and fractionated small molecule collections, derived from endemic Asian plants, has already successfully led to the identification of hit compounds in various high-throughput screening processes in other cooperations. We were curious to find out whether natural products could also demonstrate their proof-of-concept for our biochemical screening methods.’
BICOLL provided a set of 1000 Profiles (equal to approximately 3000–10,000 different small molecules) to EMBL’s biochemical screening program, which resulted in 18 hit clusters showing specific kinase activity. Because of the unexpectedly high hit rate of 2 per cent, the group of EMBL researchers elected to focus on four hit clusters for isolation and structure elucidation.
‘Within only three months and a second round of screening, BICOLL identified and structurally elucidated two pure compounds with interesting structural motifs for our client’s further development programs,’ commented Dr Kai Lamottke, Managing Director of BICOLL. ‘Subsequent investigation of our pure natural compound database, using the newly found structural motifs, additionally led to the testing in EMBL’s protein–protein interaction test. Additional compounds for further structure–activity relationship could be identified.’

Read more

Bicoll News 2010

Bicoll Newsletter Edition 2010 Successful preliminary results in a joint research project in drug discovery from natural products with our partner Genfit SA Modernization of our laboratory facilities with focus on medicinal chemistry New Advisory Board member for Bicoll – …

Read more

Bicoll and Genfit renew their alliance

The Franco-German partnership dating from 2007 between Genfit and Bicoll has announced successful preliminary results from their joint research project Olnorme, which could cement the relationship between the two companies for the long term. The Olnorme project was initiated in the
framework of the appeal for projects by EurotransBIO and funded with 3.2 M €.
Olnorme is currently an important drug research project at Genfit, based on the

screening of Profiles™ from Bicoll’s highly diversified library of plant metabolites.

Read more

Medikamentenentwicklung – Naturstoffe aus China

Asien rückt immer stärker in den Blickpunkt westlicher Pharma- und Biotechnologie-Unternehmen. War es zuvor noch der Aufbau reiner Produktionsstandorte, gerät nun auch moderne Forschung und Entwicklung immer mehr in den Brennpunkt des Interesses für Outsourcing-Aktivitäten. Hierbei bieten Indien, Singapur und China unterschiedliche Kompetenzen und Schnittstellen an.

Read more

Chinese plants for modern drug discovery campaigns

China is getting into focus for building up and conducting pharmaceutical R&D and outsourcing activities. The reason for turning towards China is mostly politically or economically motivated. Scientific aspects often do not play an important role, but China with its huge plant biodiversity
is an ideal site for drug discovery and development starting with natural compounds.
This article gives an overview about advantages and disadvantages of natural product strategies in drug
discovery. The authors describe how to deal with small molecules from plants as valuable source for successful drug discovery campaigns and how to meet the demands and standards of Western pharmaceutical industries.

Read more

Shanghai Revisted

… I recently returned from my third trip to China in the past three years. I spent a week in Shanghai and Suzhou with C&EN Senior Correspondent Jean-François Tremblay, our Hong Kong-based reporter who arranged numerous interviews with leaders in the fine and custom chemicals, contract research, and pharmaceutical industries.

Read more

China Strides Toward Global Pharma Role

For a country that fancies itself an emerging world power backed by thousands of years of history, China has a poor record in the pharmaceutical realm. It hasn’t yet brought to market a single one of the major drugs that are sold around the world today. And China’s drug industry is far better known for graft and unsafe practices than for its positive achievements.

Read more